Method of treating chronic inflammatory diseases accompanied by immune deficiencies

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used in treating chronic inflammatory diseases accompanied by immune deficiencies. To do this, having a clinical-ambulatory immune deficiency stated, the therapeutic stage of a primary disease is followed by introducing to a patient of one-group fresh umbilical blood in an amount of three millilitres mixed with one gram of a broad-spectrum antibiotic, and one millilitre of a local anaesthetic. The above is injected three times into an infrascapular region every two days.

EFFECT: using the given invention enables providing the manifested and stable effect of increasing values of the humoral component of the immune system enabling preventing manifestations of secondary infections.

10 tbl, 2 ex

 

The invention relates to medicine and can be used for the prevention and treatment of chronic inflammatory diseases associated immunodeficiency.

Chronic inflammatory diseases now prevalent in all branches of medicine. Often they are accompanied by immunodeficiency, when the immune system is not able to activate your immune response or responds to a much lesser degree than required by the body to fight infection. In such cases, the struggle with indolent infections much more difficult. Therefore, there is a need to create a new way that was not only effective, but also accessible to the broad masses of the population.

Recently intensively developed methods of treatment of chronic inflammatory diseases associated with immunodeficiency States, through immunotherapy. One of such ways is stem cell transplantation. Sources of stem cells include bone marrow, adipose tissue, blood, and stroma of the umbilical cord and placenta. The greatest application found transplantation of hematopoietic stem cells derived from bone marrow, cord blood and peripheral blood after appropriate stimulation. According to the literature in the world held Bo is her 100 thousand transplants of stem cells from these sources (about five thousand from umbilical cord blood). And in recent years have increasingly transplantation is used in non-malignant blood diseases, autoimmune and neurodegenerative diseases, due to the existence of the phenomenon of "plasticity"inherent in stem cells [1, 4].

The question about the possibility of clinical use of allogeneic cells is discussed for a long time. And if system restore blood stem cells in the bone marrow can be translational only if the maximum matching antigens of the major histocompatibility complex of the donor and recipient, using completely incompatible stem cells umbilical cord blood is justified by the fact that even short-term presence of active cells in the lesion enough to regeneration and remodeling went more successfully.

Umbilical cord blood, though, and contains on average a smaller number of stem cells compared with bone marrow, it surpasses it in quality. This is evidenced by almost 10 times lower dose of umbilical cells (including CD4-positive), which is required for successful transplantation. Restoration of the immune system is more effective due to greater activity of the newly formed T cells, which reduces the likelihood of the development of a number posttransplantation complications. These differences are determined by the tsya fact, that stem cells from umbilical cord blood "younger" cells in the bone marrow. Because cord blood is the blood of the developing fetus and circulates in all its organs and tissues, it is enriched not only hematopoietic and other cells-precursors, which in certain conditions, differentiate into hepatocytes, endothelial and muscle cells, neurons, and others [1, 4].

The use of cord blood for stem cell transplantation has several advantages compared with other sources of hematopoietic cells, which are that there is a big opportunity, compared with bone marrow, the use is not fully compatible HLA system transplants, the incidence and severity of graft-versus-host below. And collecting cord blood is a safe, technically easy procedure that do not pose a threat to the health of the mother or newborn (donor) and does not require General anesthesia in the collection [6].

In General, the umbilical cord blood at the present time should be considered as a rich source of hematopoietic stem cells suitable for transplantation. And creation of a Bank of frozen cord blood will help in solving the problem of finding a suitable transplant and can be considered as a form of biological insurance life [6.

The known method of using stem cells of umbilical cord blood for treatment of mental and neurological disorders. To do this, enter nucleated cells from umbilical cord blood, obtained by the method of gradient sedimentation or centrifugation of the samples of umbilical cord blood sampling nucleated cells in the cell sediment with subsequent resuspending cooled plasma with the addition of cryoprotectant, the invention provides effective treatment of neurodegenerative diseases and schizophrenia for reducing the risk of immunopathological States due to the fact that the method of obtaining nucleated cells in umbilical cord blood excludes cultivation in the presence of alien serum, patent RU No. 2413524, IPC A61K 35/14 (2006.01), OR 25/28.

There is a method of treatment of post-traumatic encephalopathy," in which intravenous effective number of nucleated cells in umbilical cord blood, obtained by the method of gradient sedimentation or centrifugation of the samples of umbilical cord blood sampling nucleated cells in the cell sediment with subsequent resuspending cooled plasma with the addition of cryoprotectant, freezing and cryogenic storage. The invention provides effective treatment due to the fact that the method of obtaining nucleated glue is OK umbilical cord blood excludes cultivation in the presence of alien serum patent RU No. 2413523, IPC A61K 35/14 (2006.01), OR 5/28.

There is a method of treatment of diseases associated with impaired blood supply to tissues, which includes the introduction in the blood mononuclear cells of umbilical cord blood donor. The cells of the donor have a set of antigens HLA-A, HLA-B, HLA-DR, distinct from the set of antigens HLA-A, HLA-B, HLA-DR recipient not less than four antigens. The number of input cells from 2.5×106up to 10×106per kg of body weight per day. The introduction is repeated from 2 to 10 times with an interval of 10-60 days. The method provides for the replacement of dead and/or not able to regenerate cells of the recipient specified by the donor cells and to reduce the frequency of immunopathological reactions by reducing the amount of typing mononuclear cells from a donor, patent RU No. 2284190, IPC A61K 35/14 (2006.01), OR 9/10.

There is a method of treatment of chronic hepatitis or cirrhosis. For this exercise introduction into the blood of the patient such mononuclear cells in cord blood donor, which have a set of antigens HLA-A, HLA-B, HLA-DR, distinct from the set of antigens HLA-A, HLA-B, HLA-DR recipient not less than four antigens. The number of input cells from 2.5×106up to 10×106cells per kg of body weight per day. The introduction of mononuclear cells in umbilical cord blood donor is from 2 to 10 times at intervals of 1-60 days. With the introduction of smaller, compared to known doses of mononuclear cells in umbilical cord blood provides the normalization of clinical and biochemical parameters and effective reduction of copies of HCV in the blood of patients and reduction of toxic or immunopathological reactions, patent RU No. 2295351, IPC A61K 35/14 (2006.01), OR 1/16.

The disadvantages of the above methods are limited scope, the duration of the execution, the complexity and high cost, requiring special equipment.

The closest in technical essence to the present invention is a method of treating HIV infection with obvious clinical manifestations. The method consists in cleaning the body of the patient from different viruses, including, first and foremost, from the retrovirus is the cause of AIDS (HIV), from contaminated their cells and microorganisms associated with using immunopathogenesis, alternating the use of immunoblastic. When you use for each patient individually manufactured, respectively, polystyrene film or sorbent supplied covalently fixed on them by specific antibodies (from hyperimmune serum in the immunization of the rabbit hemocultures from the patient) and CD4-rectory protein (in the form of a commercial preparation), reinforcing swazilan the e HIV in conditions in vitro held cleaning the body from HIV infection; the procedure of the process is supplemented by subsequent replenishment of damaged conditions AIDS macrophages and T-helper (T4or CD4-) cells by intraosseous transplantation of pre-concentrated umbilical cord blood (from the clip during delivery of the placenta), which contains all the necessary stem cells, the precursors of geolycosa; procedures continuous extracorporeal circulation of blood purification methods immunopathogenesis and immunoblastic completed course application specific immunostimulation with autovaccine, prepared in each case based on inactivated by UV-irradiation of hemoculture from the patient. The way HIV treatment is effective for the treatment of various forms of non-specific immunosuppression, various slow viral infections, including prion, viral hepatitis and other (in terms of certain modifications of these methods EN NO. 98107018 AND (51). The disadvantage of this method is the high invasiveness (the possibility of developing iatrogenic osteomyelitis), as well as the need to create certain conditions for transplantation (operating).2199999 (1997-2003), RF patent № 2146930, IPC A61K 35/ 16, AM 1/36.

The new technical task is to facilitate the method, the reducing treatment time by reducing the number of complications, the mod is emyh the trauma and risk of infection the expansion of the scope

To solve the problem in the treatment of chronic inflammatory diseases associated immunodeficieny States, which consists in the transplantation of umbilical cord blood, after a stage of treatment of the underlying disease and the clinical-outpatient confirmation immunodeficiency patient is injected fresh single-group of unrelated donor umbilical cord blood in a volume of 3 ml, pre-mixed with 1 g of the broad-spectrum antibiotic and 1 ml of local anesthetic, the resulting mixture is injected into the subscapularis region of three injections with an interval of two days.

The method is as follows: the patient with chronic inflammatory disease involving immune defficiency, after a stage of treatment of the underlying disease and the clinical-outpatient confirmation immunodeficiency injected fresh single-group of unrelated donor umbilical cord blood in a volume of 3 ml, pre-mixed with one gram of broad-spectrum antibiotic and one ml of local anesthetic, the resulting mixture is injected into the subscapularis region of three injections with an interval of two days. The mixture can be used, for example, the antibiotic Cefazolin and 2% lidocaine.

The mode is the manual is based on the analysis of the results of clinical observation of patients with chronic inflammatory diseases, accompanied by immunodeficiency.

During the research it was found that this volume of umbilical cord blood, three milliliters, is optimal for stimulation of the immune response. You must use fresh umbilical cord blood, as, according to the literature, a solution of dimethyl sulfoxide used for cryopreservation of stem cells, can cause moderate pulmonary and systemic toxic reactions, whereas reinfused fresh allogenic components do not have such consequences [7]. This volume of cord blood is mixed with one gram of broad-spectrum antibiotic (cephalosporin I generation Cefazolin) to prevent local infectious complications and with one ml of local anesthetic (2% lidocaine). Antibiotic prophylaxis is carried out in accordance with current clinical recommendations for antimicrobial therapy. When "clean" manipulation in hospitals with low frequency And MRS (<10%) to prevent the development of infection once it is recommended to enter Cefazolin 1-2 g or Amoxicillin/Clavulanate 1.2 g or Cefuroxime 1.5 g or Allergy to beta-lactams, Clindamycin 0.9 g and Gentamicin 5 mg/kg [2, 3]. The resulting mixture was injected into the subscapularis region, where the subcutaneous layer is sufficiently developed, and this area is much less susceptible mechanicalcowforsale from the outside. The multiplicity interval is forty-eight hours, which is due to the fact that the immune system is activated within 24-48 hours [5, 8, 9]. The course is three injections, according to the research data is sufficient for stimulation of nonspecific resistance of the organism, increasing the reparative ability of the immune system and save pronounced and persistent effect.

The new method is the use of single-group umbilical cord blood volume three milliliter, which is mixed with one gram of broad-spectrum antibiotic and one ml of local anesthetic followed by the introduction of the mixture into subscapularis region of three injections with an interval of two days.

Only the study involved nineteen patients scheduled clinic of hospital surgery and twelve patients scheduled clinic of obstetrics and gynecology, Siberian state medical University.

Surveyed patients of the clinic of hospital surgery belonged to different age groups: from 20 to 40 years - six patients, which is 32%; 41-60 thirteen patients, which is 68%. All patients with osteomyelitis of the sternum, the duration of the disease from one to three years. All patients were operated on this disease, the process has not been eliminated. the hospital prior to surgery was from three to seven days, antibiotic prophylaxis before surgery was not performed. Patients underwent surgery in the amount of resection of the sternum with the restoration of the skeleton of the sternum using synthetic materials. Postoperative complication is pneumonia in two patients.

Patients were divided into five groups depending on the volume injected umbilical cord blood:

1) three patients were injected umbilical cord blood in a volume of one milliliter;

2) four patients were injected umbilical cord blood in volume two milliliters;

3) five patients were injected umbilical cord blood in volume three milliliters;

4) four patients were injected umbilical cord blood in volume four milliliters;

5) three patients were injected umbilical cord blood in volume five milliliters.

Method of sampling of umbilical cord blood

Umbilical cord blood was obtained at physiological and operative delivery with regard to the informed consent of the mother and the absence of standard contraindications after careful prenatal diagnosis. After clamping and crossing the umbilical cord was produced by the puncture of the umbilical cord with a needle, which is part of the standard system for the collection of donor blood containing anticoagulant (containers plastic single CPDA-1 250 GG, Terumo). The material obtained was stored in a dark place at room temperature and used within 6 hours after pried the market of cord blood collection. Used umbilical cord blood-compatible system the ABO system and Rh (rhesus system) from the donor and the recipient. HLA-compatibility studies have not been conducted.

Research method immunological parameters. Determining the concentration of immunoglobulin M (0,37-1,95 g/l), G (by 5.87-16.3 g/l) in blood was carried out by radial immunodiffusion according to Mancini using monospecific sera firm "Ambio" (Russia). (The results of the study are given in Table. 1-5)

Immunological indicators of the state of anti-infective protection in patients with osteomyelitis of the sternum before surgery: IgM (g/l) and 0.40±0,20, IgG (g/l) 5,10±1,40.

One patient from the first group and one patient from the second group saw a decline in indicators of humoral immunity along with the transition phase of disease remission in aggravation. With the introduction of one and two ml of umbilical cord blood for optimal stimulation of the immune response according to the indicators of humoral immunity is not enough. With the introduction of cord blood volume three, four and five milliliters indicators of humoral immunity is improved to about the same numbers and stably kept for one year. Thus, the volume of cord blood three milliliters is the best.

Acute graft versus host up to 100 days, chronic is eacce graft-versus-host over 100 days after the first injection of umbilical cord blood in patients was not identified.

Example 1

Patient K., 52 years old, enrolled in a planned manner in the surgical Department of the hospital clinic SSMU complaining of aching pain in the sternum with radiating to the right shoulder and intercostal space to the right on average subclavian line, aggravated by movements in the upper shoulder girdle.

The patient was subjected to operative treatment in the Institute of Cardiology in volume Benamargosa bypass about stenoziruyuschego atherosclerosis of the coronary arteries (coronary artery disease, angina). Made osteosynthesis three wire ligatures. In the postoperative period she developed complications: mediastinic, exudative pleurisy, pericarditis, osteomyelitis of the sternum, infected wound in the sternum (Stafylococcus Aureus). On the background of antibiotic therapy, the wound was cleaned. The patient was transferred to the surgical clinic, SSMU, where the initial debridement, the wound in the projection of the sternum superimposed secondary seams. The seams are completely removed on the twelfth day, healing by primary intention. A month later, recurrence of osteomyelitis of the sternum, abstsedirovanie in the projection of the upper third of the sternum, breeding and draining fistulous course, bandaging. On conservative therapy, the wound cleaned, the process is stable. The patient was discharged to outpatient treatment, where were held regularly washing wounds, per the binding. Months later, the patient was enrolled in a planned manner with the above complaints.

An objective examination of the thorax cylindrical, evenly participates in the act of breathing. In the projection of the sternum in the midline (in the direction of the scar) in the upper third and lower two thirds of the wounds respectively one and two centimeters and two to three centimeters, a depth of from one half to two inches, with sluggish granulations places fibrin, pus no, the bottom of the wound is the front wall of the sternum, are determined by the wire ligatures. Palpation and pressure on the sternum in the upper third and lower third of the sternum moderate pain, crepitus is not defined.

When examining immunological indicators of the state of anti-infective protection before surgery: IgM (g/l) of 0.38, IgG (g/l) 5,11.

Blood group first (0). Rhesus factor positive.

Spiral computed tomography: State after Benamargosa bypass, a sternotomy. Mediastinic, exudative pericarditis, osteomyelitis of the sternum, the inflammatory process with the formation of a tissue defect in skin and subcutaneous fat of the anterior chest wall.

Scintigraphy with TC-technetium: defines hyperfixation RN high intensity in the sternum with a slight spread into the mediastinum. Conclusion: Scintigraphic pattern in palielinamo process in the breastbone and the surrounding soft tissues with little spread to the mediastinum.

Radiography of the chest: Pulmonary ventilation hypertension of the first degree. Condition after Benamargosa bypass. Chronic osteomyelitis of the sternum.

Clinical diagnosis: Chronic sternomastoid. Condition after full median sternotomy and the osteosynthesis wire ligatures.

Postoperative instability of the sternum.

In the hospital before surgery, the patient was five days, the antibiotic prophylaxis prior to surgery was not performed. Performed surgery in the amount of resection of the sternum with the restoration of the skeleton of the sternum using synthetic materials. The wound is sutured, leaving patroncito drainage. The drainage was removed on the second day after surgery. Sutures were removed on the fourteenth day after the operation. Postoperative wound healing by primary intention. The postoperative period was uneventful. Given the history of the disease - decrease in humoral immunity and complications during the treatment was conducted according to the proposed method, which on the twelfth day the patient in subscapularis region was introduced fresh single-group of unrelated donor umbilical cord blood in volume three milliliters of pre-mixed with one gram of broad-spectrum antibiotic (cephalosporin I generation Tsefa the Olin) and one ml of local anesthetic (2% lidocaine), after setting the injection, the patient felt satisfactory. Immunological indicators of the state of anti-infective protection of the patient on the fourteenth day after surgery: IgM (g/l) of 0.44, IgG (g/l) 6,0. On the same day re-entered the umbilical cord blood on a similar scheme. Immunological indicators of the state of anti-infective protection of the patient on the sixteenth day after surgery: IgM (g/l) of 0.51, IgG (g/l) of 6.9. On the same day, held the third injection of umbilical cord blood for a similar scheme. Immunological indicators of the state of anti-infective protection of the patient on the eighteenth day after surgery: IgM (g/l) of 0.62, IgG (g/l) 8,10. In a satisfactory condition the patient was discharged on the twentieth day after the operation. In routine outpatient examinations in up to two years the patient after surgery no complaints, working. When carrying out x-ray control of the chest signs of recurrence of osteomyelitis of the sternum is not revealed. Immunological indicators of the state of anti-infective protection of the patient six months after the last injection of umbilical cord blood IgM (g/l) of 0.79, IgG (g/l) 10,30. Immunological indicators of the state of anti-infective protection of the patient twelve months after the last injection of umbilical cord blood IgM (g/l) 0,80, IgG (g/l) 12,70. Immunol the environmental condition indicators and anti-infective protection of the patient two years after the last injection of umbilical cord blood IgM (g/l) of 0.96, IgG (g/l) 13,40.

Surveyed patients of the clinic of obstetrics and gynecology belonged to different age groups:

from 20 to 30 years - four patients, representing 33%;

- from 31 to 40 years - eight patients, accounting for 67%.

All patients with chronic diseases of the pelvic organs, the duration of the disease from two to five years. All patients already underwent conservative treatment for this disease at least three times, long-term remission was not observed.

The patients were divided into five groups depending on the volume injected umbilical cord blood:

1) two patients were injected umbilical cord blood in a volume of one milliliter;

2) two patients were injected umbilical cord blood in volume two milliliters;

3) three patients were injected umbilical cord blood in volume three milliliters;

4) three patients were injected umbilical cord blood in volume four milliliters;

5) two patients were injected umbilical cord blood in volume five milliliters.

Immunological indicators of the state of anti-infective protection of patients before the introduction of umbilical cord blood IgM (g/l) 0,35±0,15, IgG (g/l) 4,80±1,10 (the data obtained are presented in Table. 6-10).

Two patients from the first group and one patient from the second group saw a decline in indicators of humoral immunity along with the transition phase of disease remission in aggravation. When BB is Denia one and two ml of umbilical cord blood for optimal stimulation of the immune response according to the indicators of humoral immunity is not enough. With the introduction of cord blood volume three, four and five milliliters indicators of humoral immunity is improved to about the same numbers and stably kept for one year. Thus, the volume of cord blood three milliliters is the best.

Acute graft versus host up to 100 days, chronic graft versus host over 100 days after the first injection of umbilical cord blood in patients was not identified.

Example 2

Patient M., aged 35, arrived in a planned manner in the gynecological clinic SSMU with complaints of fever up to 38°C, aching pain in the region of hypogastric, radiating into the left iliac region.

The patient two years ago diagnosed with chronic salpingo-oophoritis, relapses occur three to four times a year, last time was hospitalized three months ago with a similar episode of exacerbation.

An objective examination of the abdomen is rounded, symmetrical. Palpation of soft, painful in the lower divisions, mainly in the left iliac region, signs of peritoneal irritation are not defined. Status genitalis: the body of the uterus is not enlarged, flexible, somewhat painfully at offset. The appendages on the right is not enlarged, condensed, painless on palpation. Appendages to the left slightly increased, pasty, bresnen the palpation. The cervix when viewed in the mirrors are not visually changed, the allocation of scarce light.

By ultrasound pelvic data for volumetric education of appendages is not detected, the liquid in papadimitrou space no. When examining immunological indicators of the state of anti-infective protection before the introduction of umbilical cord blood IgM (g/l) of 0.38, IgG (g/l) 5,11. Clinical diagnosis: Chronic oophoritis, acute stage.

In the hospital, where he held conservative therapy, the patient was twelve days. On the second day after admission the patient in the subscapularis region was introduced fresh single-group of unrelated donor umbilical cord blood in volume three milliliters of pre-mixed with one gram of broad-spectrum antibiotic (cephalosporin I generation Cefazolin) and one ml of local anesthetic (2% solution lidocaine), after setting the injection, the patient felt satisfactory. Immunological indicators of the state of anti-infective protection of the patient on the fourth day after admission (setting the first dose of the mixture carried out on the second day after admission): IgM (g/l) of 0.50, IgG (g/l) 6,10. On the same day re-entered the umbilical cord blood on a similar scheme. Immunological parameters status the I anti-infective protection of the patient on the sixth day after admission: IgM (g/l) of 0.60, IgG (g/l) 8,90. On the same day, held the third injection of umbilical cord blood for a similar scheme. Immunological indicators of the state of anti-infective protection of the patient on the eighth day after admission (setting the third dose made on the sixth day after admission): IgM (g/l) to 0.72, IgG (g/l) 10,10. The patient was discharged in satisfactory condition.

In routine outpatient examinations in up to two years after the introduction of umbilical cord blood, the patient had no complaints, the able-bodied. In routine ultrasound examination of the pelvic organs data for pathology it is not revealed.

Immunological indicators of the state of anti-infective protection of the patient six months after the last injection of umbilical cord blood IgM (g/l) of 0.85, IgG (g/l) 12,30. Immunological indicators of the state of anti-infective protection of the patient twelve months after the last injection of umbilical cord blood IgM (g/l) of 0.90, IgG (g/l) 13,70. Immunological indicators of the state of anti-infective protection of the patient two years after the last injection of umbilical cord blood IgM (g/l) of 1.05, IgG (g/l) 14,80.

In clinical conditions, the technique is applied on five patients with osteomyelitis of the sternum with a positive effect on three patients with chronic diseases of the appendages. The results of the experimental Stalnoy testing confirm the efficiency of the proposed method and achievable technical result.

The method allows to obtain a strong and persistent effect, to prevent manifestations of secondary complications, improve the immune status of the organism. The method can be used for the treatment of chronic and slow current of infections of different origin and localization.

Sources of information

1. Weintal J., Lenarsky K., Goldman, S. Children's Hospital, North Texas, Dallas, pediatric Oncology program, Texas, 2002. Pediatric Oncology, 2003, 3. P.4-6.

2. R.S. Kozlov, Technic AV current clinical guidelines for antimicrobial therapy. Issue 2. - Smolensk: IACMAC, 2007 - 608 S.

3. R.S. Kozlov, Technic AV Handbook of antimicrobial therapy. Issue 2. - Smolensk: IACMAC, 2010 - 416 S.

4. Fingers M.A., Ivanov A.A., Smirnov V.N., Romanov, Y.A. Stem cells in modern medicine: present and future. Molecular medicine, 2006, 2. Pp.5-9.

5. Petrov R.V. Immunology. - M.: Medicine, 1983, 368 S.

6. Tkachenko VV method for the treatment of HIV infection. Patent 2199999 (1997-2003) Class(es) of the patent: A61K 35/16, AM 1/36. Patent number: 2146930. Application number: 98107018/14. Date of application: 10.04.1998,

7. Shiffman FJ. Pathophysiology of blood. TRANS. from English. - M - SPb.: "Publishing BINOM. Nevsky Dialect", 2000 - 448 C., Il.

8. Arianna Malgieri, Eugenia Kantzari, Maria Patrizia Patrizi, and Stefano Gambardella. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. International Journal of Clinical and Experimental Medicine. 201; 3(4):248-269.

9. Julia Brown, Vassiliki A. Boussiotis. Umbilical Cord Blood Transplantation: Basic Biology and Clinical Challenges to Immune Reconstitution. Clin Immunol. 2008 June; 127(3):286-297.

Table 1

Immunological indicators of the state of anti-infective protection in patients with osteomyelitis of the sternum 14 days after surgery (setting the first dose of the mixture carried out for 12 hours after surgery)

Table 2

Immunological indicators of the state of anti-infective protection in patients with osteomyelitis of the sternum 16 days after surgery (arm a second dose of the mixture carried out at 14 days after surgery)

Table 3

Immunological indicators of the state of anti-infective protection in patients with osteomyelitis of the sternum 18 days after the operation (setting the third dose of the mixture made 16 days after surgery)

Table 4

Immunological indicators of the state of anti-infective protection in patients with osteomyelitis of the sternum six months

Table 5

Immunological indicators of the state of anti-infective protection in patients with osteomyelitis of the sternum twelve months

Table 6

Immunological indicators of the state of anti-infective protection of patients on the fourth day after admission (setting the first dose of the mixture carried out on the second day after admission)

Table 7

Immunological parameters with the situation of anti-infective protection of patients on the sixth day after admission (setting the second dose of the mixture carried out on the fourth day after admission)

Table 8

Immunological indicators of the state of anti-infective protection of patients on the eighth day after admission (setting the third dose of the mixture carried out on the fourth day after admission)

Table 9

Immunological indicators of the state of anti-infective protection of patients after six months

Table 10

Immunological indicators of the state of anti-infective protection in patients twelve months

Table 1
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,35±0,105,80±1,40
Two milliliters0,40±0,205,9±1,80
Three milliliters0,50±0,106,10±1,30
Four milliliters0,50±0,106,10±0,50
Five milliliters0,50±0,20 6,20±0,80

Table 2
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,40±0,105,80±1,40
Two milliliters0,40±0,206,00±1,20
Three milliliters0,55±0,108,10±0,50
Four milliliters0,60±0,10of 7.90±0,50
Five milliliters0,55±0,40to 8.20±0,40

Table 3
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,40±0,106,00±0,80
Two milliliters0,45±0,106,90±0,70
Three milliliters0,70±0,3011,10±1,10
Four milliliters0,80±0,3011,70±0,50
Five milliliters0,85±0,1010,90±1,30

12,80±1,80
Table 4
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitreOh,35±0,305,80±1,40
Two milliliters0,50±0,306,0±0,80
Three milliliters1,10±0,4012,10±1,50
Four milliliters1,00±0,1013,40±1,10
Five milliliters1,30±0,40

Table 5
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,40±0,305,80±1,30
Two milliliters0,70±0,308,30±1,80

Three milliliters1,20±0,4013,10±1,10
Four milliliters1,30±0,1013,60±1,10
Five milliliters1,35±0,4012,80±1,40

Table 6
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre 0,35±0,105,80±1,40
Two milliliters0,40±0,205,9±1,80
Three milliliters0,50±0,107,10±1,30
Four milliliters0,65±0,10to 8.20±0,50
Five milliliters0,55±0,208,00±0,80

Table 7
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,40±0,105,80±1,40
Two milliliters0,40±0,206,00±1,20
Three milliliters0,55±0,108,10±0,50
Four milliliters0,60±0,10of 7.90±0,50
Five millili is s 0,55±0,40to 8.20±0,40

Table 8
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,40±0,106,10±0,80
Two milliliters0,40±0,10of 7.90±0,50
Three milliliters0,75±0,2010,10±0,70
Four milliliters0,90±0,3011,70±0,50
Five milliliters0,85±0,1010,90±1,30

Table 9
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre 0,35±0,205,80±0,70
Two milliliters0,50±0,15of 7.90±0,80
Three milliliters1,10±0,4012,90±0,60
Four milliliters1,30±0,1013,40±1,10
Five milliliters1,40±0,1513,80±1,20

Table 10
The volume of injected umbilical cord bloodSerum
IgM (g/l)IgG (g/l)
One millilitre0,40±0,306,90±0,90
Two milliliters0,55±0,108,30±1,80
Three milliliters1,10±0,10the 14.90±1,40
Four milliliters1,40±0,3015,00±1,10
Five mill is liters 1,45±0,5014,80±1,80

1. A method of treating chronic inflammatory diseases associated with immunodeficiency States, by transplantation of umbilical cord blood, characterized in that after the step of treatment of the underlying disease and the clinical-outpatient confirmation immunodeficiency injected fresh single-group of unrelated donor umbilical cord blood in volume three milliliters of pre-mixed with one gram of broad-spectrum antibiotic and one ml of local anesthetic, and the resulting mixture was injected into the subscapularis region of three injections with an interval of two days.

2. The method according to claim 1 characterized in that the mixture using a cephalosporin antibiotic.

3. The method according to claim 1 characterized in that the mixture using a local anesthetic 2% lidocaine.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is an agent for poly(ADP-riboso)polymerase inhibition. The agent represents 7-methylguanine(2-amino-7-methyl-1H-purin-6(7H)-one)- a purine derivative of formula (I) The agent has shown the efficacy higher than that in 7-methyl-xanthine and is non-toxic for the human body.

EFFECT: agent can be used in treating conditions caused by necrotic cell death: stroke, myocardial ischemia, diabetes and complications thereof, shock, neurotrauma, arthritis, colitis, allergic encephalomyelitis and other inflammations.

1 dwg, 2 ex

FIELD: biotechnology.

SUBSTANCE: composition is proposed which comprises stem cells of human amniotic fluid with the phenotype CD73+/CD90+/CD105+/CK19+, nutrient medium, erythropoietin, epidermal growth factor, and collagen taken in an effective amount.

EFFECT: invention enables to increase the proliferative potential and viability of the cells, while simultaneously providing cytoprotective effect on the cells of the transplant and stimulation of migration and proliferation of patient's own cells, and also to reduce significantly the concentration of injectable cells and to activate vascularisation and regeneration at the defect site and can be used in therapy for elimination of congenital and acquired defects of soft tissue arising as the result of injuries, after removal of tumors, congenital diseases, age-related changes or other damages.

2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention represents a pharmacological geroprotective composition, which includes a polyphenol component, vitamins and microelements, humic acids, containing polyphenol components, vitamin C, vitamin A, iron (II) chloride and selenium (IV) dioxide, with the composition components being in a specified ratio in wt %.

EFFECT: increased life expectancy and retardation of tumour development.

2 cl, 3 dwg, 2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of general formula (I) or pharmaceutically acceptable salts thereof, where Alk is an C1-C6alkyl group; G is C=O and Q is CR51R52 or NR51, where R51 and R52, being identical or different, independently denote H, C1-C6alkyl, optionally substituted with a substitute selected from a group comprising carboxy, phenoxy, benzyloxy, C1-C6alkoxy or hydroxy; C3-C6cycloalkylC1-C6alkyl; phenylC1-C6alkyl, optionally substituted with a halogen; phenylamidoC1-C6alkyl; phenylC1-C6alkylamidoC1-C6alkyl, optionally substituted with a C1-C6alkoxy group; or R51 and R52, together with a carbon atom with which they are bonded form a C=O or C2-C6alkenyl group, optionally substituted with a phenyl; M1 is CR49, where R49 is H; M2 is CR50, where R50 is H; R38 is H, C1-C6alkyl, substituted with a phenoxy group; C3-C6cycloalkylC1-C6alkyl; arylC1-C6alkyl, optionally substituted with 1 or 2 substitutes selected from a group comprising C1-C6alkyl, C1-C6alkoxy, C1-C6alkoxycarbonyl, carboxyl, N-methylamido, hydroxy, C1-C6alkoxyC1-C6alkoxy, C1-C6alkylthio, C1-C6alkylsulphanyl, cyano, halogen, perfluoroC1-C6alkyl, nitro, formyl, hydroxyC1-C6alkyl and amino, wherein the aryl moiety is a phenyl or naphthyl; and heteroarylC1-C6alkyl, where the heteroaryl moiety is pyridinyl, optionally substituted with 1 or 2 groups selected from C1-C6alkoxy or hydroxyC1-C6alkyl, pyrazolyl or isoxazolyl, substitute with 1 or 2 C1-C6alkyl groups; R47 and R48 is C1-C6alkyl. The invention also relates to specific compounds, a method of reducing or weakening bitter taste, a composition of a food/non-food product or beverage or drug for reducing or lightening bitter taste and a method of producing a compound of formula (I).

EFFECT: obtaining novel compounds which are useful as bitter taste inhibitors or taste modulators.

37 cl, 6 dwg, 12 tbl, 186 ex

FIELD: medicine.

SUBSTANCE: halogen-containing hydrocarbonate chloride sodium, alkaline, boron high-magnesium, iodine and fluorine natural mineral water 'Lazarevskaya Tselebnaya' No. 84-E of the Volokonskoye deposite in Sochi is taken according to the following procedure: 30-35 minutes before meals in small sips, six times a day daily in a dose of 200-250 ml at t°=(23-24)°C, for 45 days every 2-3 days with taking the above natural halogen-containing mineral water in the same volumes for the following 45 days. The therapeutic course makes 3 years.

EFFECT: method enables improving the health status in the individuals subject to the hazardous effect of radionuclides taken with water or food.

2 cl, 6 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: food ration is added with multi-component natural concentrated food products (NCFP) with high concentrations of biologically active substances (BAS) of herbal (HNCFP) and (or) protein-herbal (PHNCFP) raw material, for the purpose of nutritional support of sportsmen doing various sports, their individual physiological requirements; that results in recovering a set of characteristics of physiological functions and qualities determining a degree of activity of morphofunctional body systems, activities of daily living and professional performance, with providing preventing donozological and pathological conditions, achieving high sport scores. The above food products can be presented by NCFP Antitox and NCFP SportAtiv-2.

EFFECT: invention provides easier exercise tolerance and recovery thereafter, improving health in sportsmen.

5 cl

FIELD: medicine.

SUBSTANCE: method involves preliminary intraperitoneal single administration of 5% aqueous alloxan in a dose of 15 mg/kg of body weight into a rat's body on an empty stomach. That is followed by administering afobazol under conditions of oxidative stress after observing the rat's blood glucose gain at least twice. Afobazol is administered subcutaneously in a dose of 10 mg/kg of body weight once a day for 30 days with underlying administration of L-arginine in a dose of 10 mg/kg of body weight or with underlying NG-nitroarginine methyl ester (L-NAME)-inhibitor of NOS-3 enzyme in a dose of 25 mg/kg of animal's weight.

EFFECT: method enables correcting the oxidative stress and NO-producing endothelial dysfunction accompanying vascular complications of diabetes mellitus.

1 dwg, 6 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to rehabilitation medicine and concerns prevention of meteopathic reactions. That is ensured by administering an adaptogene agent presented by a phytococktail containing mixed 70% tinctures of eleuterococcus, common licorice and rhodiola rosea in the ratio of 2:1:1. The cocktail is introduced in a dose of 10-15 drops for two weeks once a day, taking into account an individual's chronotype. That is followed by a magnetic-infrared-laser exposure covering the acupuncture points Tr(X)5 - Wai Guan, E(III)36 - Zuo San Li, Tr(X)15 - Tian Liao and MC(IX)5 - Jian Shi through an applicator wetted in the phytococktail containing 70% alcoholates of rhodiola rosea, common licorice, yellow starwort and spiny eleuterococcus in the ratio of 2:2:1:1, in a combination with an aromatherapy with Atlas cedar oil.

EFFECT: integrated exposure in the developed mode provides higher non-specific body resistance to meteorological factors.

2 ex, 3 tbl, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using a compound of formula (1) or its salt for preparing a drug for increasing HIF-1α stabilisation in a cell, as well as for preparing a drug enhancing the immune response in an individual, for preventive management of a wound to avoid an infection, for treatment of the microbial infection, for improvement of efficacy of a vaccine for management of the wound in the individual. What is presented is a pharmaceutical composition containing the above HIF-1α prolyl hydroxylase inhibitor and one or more additives. What is shown is achieving the declared applications by using the new compound of formula (1) with the HIF-1α prolyl hydroxylase (HIFPH2 (EGLN1)) inhibitor. It makes it applicable for treating HIF-1 alpha activity related diseases, conditions and/or syndromes.

EFFECT: preparing the drug for increasing HIF-1α stabilisation in a cell.

26 cl, 20 dwg, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: what is used is a 20% alcoholic tincture (1:10) of medicinal herbs in the following weight proportions: Rhaponticum carthamoides roots and rhizomes - 2, tormentil roots - 1, peppermint leaves - 3. A mouthwash is prescribed before a dentist's appointment for 3-4 days 3 times a day, as well as 10-15 minutes before an impression manipulation.

EFFECT: method provides reducing intensity a gag reflex accompanying dental manipulations.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a method of industrial production of fibrin-monomer from the blood plasma. The method of industrial production of fibrin-monomer from the blood plasma consists in defrosting fresh frozen human plasma with continuous mixing, with further addition into plasma of a saturated ammonium sulphate solution, the obtained mixture is kept at a temperature, after which it is centrifuged, a supernatant liquid is poured out; after that, urea is dissolved in a phosphate buffer and heated, with further dissolution in the buffer of the earlier obtained fibrinogen sediment, then, human thrombin is added and mixed; the mixture is kept at a room temperature, further, the obtained mixture is divided into three parts, the phosphate buffer is introduced into a reservoir with one of the three parts of the initial fibrinogen solution, a fibrin clot, formed in the reservoir is collected, washed in distilled water and pressed, as a result, three washed fibrin clots are obtained, after that, washing of the fibrin clot is repeated two more times in the same way, the final product - fibrin-monomer is obtained by dissolution of the washed fibrin clot in an acetate buffer with urea, the obtained fibrin-monomer is poured into flasks, after that, flasks with fibrin-monomer are frozen and freeze-dried under specified conditions.

EFFECT: method makes it possible to increase the output of fibrin-monomer.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to plastic surgery. An external boundary of the areola is incised by 1/2 of its length. Mammary tissues are separated by a blunt surgical instrument. A formed cavity is dried for an implant. Fibrin glue is introduced into the cavity and kept for 3-5 minutes. An implant is placed into the cavity. The mammary gland is shaped manually and kept for 2-3 minutes until setting of the glue. The incision is covered with a deep dermal suture with an absorbable suture. A stitch length makes no more than 5÷7 mm. An upper layer of epidermis is pulled apart, and the formed silt is filled with fibrin glue. The coupled borders are stripped, and a dry dressing is applied.

EFFECT: method enables shaping the mammary gland as necessary, minimising ptosis, and eliminating an incision scar.

2 cl, 3 ex, 12 dwg

FIELD: chemistry.

SUBSTANCE: group of inventions relates to the field of biotechnology. Claimed is a method of purification of a factor, contributing to wound healing, which represents a hepatocyte growth factor (HGF). All stages of purification are carried out in the presence of antithrombin III (AT-III). In accordance with the claimed method carried out are: defrosting of the frozen HGF-containing source and removal of sediment from the defrosted source. After that, the obtained solution, which contains a supernatant and AT-III, is brought in contact with a carrier for affinity chromatography on an immobilised heparin. Then, the solution is separated from the carrier for affinity chromatography. The carrier is brought in contact with a desorption buffer with ionic strength sufficient for HGF desorption. The desorption buffer, containing HGF, AT-III and histidine-rich glycoprotein (HRGP) is collected. Also claimed are wound-healing compositions, which contain HGF, AT-III and/or HRGP, purified by the claimed method.

EFFECT: inventions make it possible to increase step-by-step output of the hepatocyte growth factor, with the hepatocyte growth factor being concentrated in eluate in the presence of AT-III.

26 cl, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: blood is examined for angiogenic factors, namely soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF). An angiogenic factor (Ka) is calculated by formula: Ka=sFlt-1/PlGF×10. If Ka is 10 or less, the pregnant woman is stated to require no admission to hospital, no case follow-up; doctor's appointments are scheduled. If Ka falls within the range of 10 to 50, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed; an amniotic fluid index (AFI) is calculated; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 10 days. The amount of infusion makes 400 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control ultrasonography, Doppler monitoring, foetal monitoring, AFI and Ka measurements are performed 2 weeks later. The pregnant woman is discharged from hospital if observing no negative trends. If Ka falls within the range of 50 to 100, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days The amount of infusion makes 800 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control Doppler monitoring and foetal monitoring are performed every 3 days; 2 weeks later control Ka is measured. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 100 or more, but less than 150, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days. The amount of infusion makes not less than 800 ml a day with the same preparations prescribed. Those are added with the preparations for homeostasis correction, including Fraxiparine, Fragmin, Clexane optionally. Control Doppler monitoring and foetal monitoring are daily. Hypamnion also requires measuring control AFI. If a gestational age is less than 34 weeks, respiratory distress syndrome (RDS) should be prevented by administering the preparation Dexon 24 mg according to the schedule: 6 mg every 12 hours 4 times. Control Ka is necessarily measured after 2 weeks of the treatment. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 150 or more, and the gestational age is more than 34 weeks, the therapeutic approach is the same, as for Ka being within 100 to 150, control Doppler monitoring, foetal monitoring are performed twice a day, as well as measuring AFI. If observing no foetal weight gain for 2 weeks of the therapy or the functional state of the foetus deteriorates, a Cesarean section is performed. If the gestational age is 34-36 weeks, the therapeutic approach and follow-up are the same as for the gestational age of 34 weeks, except for the prevention of foetal RDS. However, if observing the deterioration of a foetal movement pattern or the functional status of the foetus, a Cesarean section is performed according to the foetal monitoring and Doppler monitoring findings. If the gestational age is more than 36 weeks, and Ka is 150 or more, pre-mature delivery is applied.

EFFECT: optimal selection of the therapeutic approach ensured by determining the values reflecting the severity of the cardiovascular disorder directly in the uterine-placental complex and mother's and foetus's compensatory capacities.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for preventing chronic fatigue syndrome in males. The agent for preventing chronic fatigue syndrome in males is presented in the form of suppositories containing male red deer's blood plasma, dry sweetvetch extract, L-arginine and additives in certain proportions.

EFFECT: agent is effective to prevent chronic fatigue syndrome in males; it corrects the psychoemotional status, and also promotes the activation of testosterone synthesis.

FIELD: medicine.

SUBSTANCE: what is used is a targeted transport of antibacterial drugs to an area of inflammation by a single use of an extracorporeal antibiotic therapy including the antibiogram findings. With underlying intraoperative autologous blood donation combined with hypervolemic haemodilution and neuraxial anaesthesia, the infusion is followed by an autologous blood exfusion in a volume of 5-10 ml/kg of body weight with the total volume of the infusion dominating over the volume of the autologous blood exfusion by 130-140%, with the autologous blood reinfusion following a surgical haemostasis.

EFFECT: invention reduces the postoperative inflammatory complications in high-risk groups, enables reducing a therapeutic dose and a frequency of administration of a drug, eliminating or reducing the amount of transfused blood components, avoiding an adverse effect on a foetus presented in the form of the newborn's microflora change and the appearance of antibiotic-resistant forms of pathogens.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and biotechnology, and represents a method for preparing a combined antibacterial preparation for treating acute intestinal infections. The invention is to prepare a biological ingredient biomass representing a complex of immunoglobulins or bifidus bacteria biomass, to mix it with an antibiotic substance in specified proportions, and differs from the known analogues by the fact that mixing the two ingredients of the preparation is preceded by grinding the biological ingredient only to be ground to the greatest maximum bulk density of the ground material.

EFFECT: invention improves the antibacterial activity of the combined preparation, which leads to reducing the length of treating an acute intestinal infection.

2 cl, 1 tbl, 3 ex

FIELD: biotechnologies.

SUBSTANCE: in order to obtain a biologically active substance after electric stimulation of chicken heads, blood is taken and incubated in the mode with voltage of 100-120 V, current force of 3-5 A during 3-5 seconds. Then, a serum is separated. A polypeptide fraction with molecular weight of 150-170 kilodalton is extracted from it. The obtained peptide fraction is lyophilised and sterilised by irradiation in a linear electron accelerator with a dose of 28-32 kGy. The invention can be used to obtain a remedy providing stimulation of proliferation of non-differentiated cells of human marrow, which can be used at treatment of oncohematological and autoimmune diseases.

EFFECT: preserving ability of non-differentiated cells of marrow to differentiation in a patient organism owing to excluding an inhibiting effect of an agent that stimulates proliferation; increasing a proliferation speed of non-differentiated cells of human marrow; reducing complications determined by immunogenic activity of the agent that stimulates proliferation, at use of an agent obtained by means of the proposed method; cheapening, simplifying the method owing to using available raw material.

2 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, therapy of patients suffering lung cancer and having contraindications to the surgical management. There are prescribed autohemochemotherapy (AHCT) that is administering chemopreparations incubated with autoblood, and radiation therapy (RT). Pre-therapeutic blood prolactin and progesterone are measured, and before the beginning of the AHCT, the patient starts taking bromocriptine 2.5 mg once a day with food; besides, oxyprogesterone capronate 1 ml is administered intramuscularly twice a week every 3 days. That is followed by the AHCT course consisting of 1-3 administrations of autoblood CP, and if observing a complete tumour resorption, the surgical management to the extent of pneumoectomy is supposed to follow, while a partial resorption observed two weeks after the last auroblood CP administered, implies the RT: at first 2 Gy twice a day every 4-5 hours starting from 5 days a week to achieve a basic dose of 28 Gy. That is followed by a 2-week pause, then 4 Gy daily, 3 radiation fractions a week, 6 fractions in total, up to a total radiation dose of 52 Gy for the whole RT course. Throughout the treatment, the patient keeps taking bromocriptine and oxyprogesterone capronate with controlling the blood prolactin and progesterone values: as compared to the pre-therapeutic values, prolactin is expected to fall to the end of the treatments, while progesterone - to rise.

EFFECT: method provides improving the conservative therapeutic effect in the patients of the given group: downsizing the tumour and lymph nodes until the primary tumour regresses completely by 30%, and the patients change to the resectable state; improving the patient's quality of life.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. A preparation for the prevention of diarrhoeas in newborn calves containing acid hydrolysate of animal blood, lactic, benzoic, succinic acids, additionally contains acetic acid, in the following ratio, wt %: acetic acid 0.4-0.5, lactic acid 0.05-0.06, benzoic acid 0.04-0.05, succinic acid 0.02-0.03, acid hydrolysate of animal blood - the rest.

EFFECT: invention provides a lower probability of diarrhoeas in the newborn calves and reducing a mortality rate.

3 tbl, 6 ex

FIELD: medicine, surgery.

SUBSTANCE: at the background of basic therapy in complex therapy of acute pancreatitis one should introduce ceruloplasmin to be applied at the dosage of 600-1000 mg/d for 5 d. If necessary, the course of ceruloplasmin introduction should be repeated. This method provides pancreatic tissues viability in case of pancreonecrosis by increasing efficiency of correction the endogenous intoxication and decreasing the number of complications in the course of therapy conducted.

EFFECT: higher efficiency of pharmacological correction.

3 ex

Up!